Lazard Capital Downgrades Orexigen Therapeutics (OREX) to Sell
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Price: $0.22 --0%
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Lazard Capital downgraded Orexigen Therapeutics (NASDAQ: OREX) from Neutral to Sell with a price target of $0.25.
The firm said the prospects for Contrave remain bleak.
For more ratings news on Orexigen Therapeutics click here and for the rating history of Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $1.47 yesterday.
The firm said the prospects for Contrave remain bleak.
For more ratings news on Orexigen Therapeutics click here and for the rating history of Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $1.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
